A randomised, open-label study to compare the effect of new-onset therapy with PEGASYS [peginterferon alfa 2a], and continuation therapy with adefovir dipivoxil or lamivudine, on viral response in patients with chronic hepatitis B pre-treated with adefovir dipivoxil or lamivudine

Trial Profile

A randomised, open-label study to compare the effect of new-onset therapy with PEGASYS [peginterferon alfa 2a], and continuation therapy with adefovir dipivoxil or lamivudine, on viral response in patients with chronic hepatitis B pre-treated with adefovir dipivoxil or lamivudine

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Nov 2015

At a glance

  • Drugs Adefovir dipivoxil; Lamivudine; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 23 Feb 2010 Planned number of patients changed from 140 to 14 as reported by Roche record.
    • 17 Jul 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top